Christopher Rovaldi

Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA.

Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA.

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million.

Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ.